Additional information regarding our current recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma can be found in the following articles:

RMC pathogenesis:

  • A hypothetical model of RMC pathogenesis postulating that INI1 (SMARCB1) deletions and translocations can occur via the deregulation of low fidelity DNA repair pathways due to regional ischemia induced by red blood cell sickling in the renal inner medulla, most commonly in the right kidney.